Testing
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Do you want to take a closer look?

Understand the importance of biomarkers in the management of your patients with NSCLC

The importance of testing your NSCLC patients for METex14 skipping

The importance of testing your patients with NSCLC for METex14 skipping

≤4%

of patients like yours may harbor METex14 skipping1–4

NGS

testing can accurately detect METex14 skipping, and is encouraged by global guidelines5–7

METex14 skipping at first diagnosis can help identify the appropriate disease management6

Up to 4% of patients like yours are living with a METex14 skipping subtype alteration associated with poor prognosis.1–4  A study assessing the overall survival in patients with METex14 skipping NSCLC demonstrated that those who harbor this alteration have a significantly shorter OS compared to those without.8 

MET alterations, including METex14 and METamp, can be identified using either tissue or liquid biopsies6

Having a choice of biopsies could offer both reliability and flexibility in your testing approach.6  

 

Tissue biopsies are considered the gold standard approach to diagnosis of NSCLC, but there is an increasing uptake of non-invasive approaches in biomarker testing in clinical practice.6

 

Liquid biopsies offer the ability to monitor a patient’s response to therapy and identify resistance mutations in patients without the need for repeat tissue biopsies.6

 

Liquid biopsies involve the analysis of circulating tumor DNA in the plasma and can provide flexibility and ease of access.6 Concordance between tissue and liquid tumor biopsies has been shown to be >90%, positioning liquid biopsies as an important yet underutilized

tool in NSCLC.

Global guidelines encourage a broad array of biomarker testing6

There are multiple platforms that can be used to test for gene mutations, including IHC, FISH, RT-PCR and NGS. 


Of these, NGS is the most frequently used diagnostic tool.9 Including METex14 in your liquid or tissue diagnostic panel could help you monitor for alterations in your patients with NSCLC.6

References and Abbreviations

Expand all Collapse all

FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; OS, overall survival; RT-PCR, reverse transcription polymerase chain reaction 

 

1. Salgia R. Mol Cancer Ther 2017; 16:555–565.

2. Ikeda S et al. J Hematol Oncol 2018; 11:76. 

3. Wang Q et al. J Hematol Oncol 2019; 12:63. 

4. Sterlacci W et al. Virchows Arch 2017; 471:49–55.

5. Kim EK et al. Clin Lung Cancer 2019; 20:e123–e132. 

6. Pennell NA et al. Am Soc Clin Oncol Edu Book 2019; 39(531–542).

7. Chen M, Zhao H. Hum Genomics 2019; 13:34. 

8. Tong JH et al. Clin Cancer Res 2016; 22:3048–3056.

9. Kamps R et al. Int J Mol Sci 2017; 18:308. 

10. Qi ZH et al. J Cancer 2018; 9:3417–3426.

Leaving website.

This link will take you to a website to which our Privacy Policy and Conditions may not apply. Merck has no control over the contents and policies of third party sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them. 

 

 

 

Please check Privacy Policy and Conditions of the linked website.

 

 

 

Do you wish to continue and leave this site?

Are you a healthcare professional?

  

YES

  

 

NO

Not a healthcare professional? Visit our public site

Continue